Insulet EBITDA 2010-2025 | PODD
Insulet annual and quarterly EBITDA history from 2010 to 2025. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Insulet EBITDA for the quarter ending June 30, 2025 was $0.143B, a 94.57% increase year-over-year.
- Insulet EBITDA for the twelve months ending June 30, 2025 was $0.494B, a 41.97% increase year-over-year.
- Insulet 2024 annual EBITDA was $0.39B, a 33.09% increase from 2023.
- Insulet 2023 annual EBITDA was $0.293B, a 190.48% increase from 2022.
- Insulet 2022 annual EBITDA was $0.101B, a 45.04% decline from 2021.
| Insulet Annual EBITDA (Millions of US $) |
|
|---|---|
| 2024 | $390 |
| 2023 | $293 |
| 2022 | $101 |
| 2021 | $183 |
| 2020 | $107 |
| 2019 | $78 |
| 2018 | $43 |
| 2017 | $7 |
| 2016 | $3 |
| 2015 | $-33 |
| 2014 | $3 |
| 2013 | $-17 |
| 2012 | $-25 |
| 2011 | $-34 |
| 2010 | $-34 |
| 2009 | $-49 |
| Insulet Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2025-06-30 | $143 |
| 2025-03-31 | $111 |
| 2024-12-31 | $131 |
| 2024-09-30 | $109 |
| 2024-06-30 | $74 |
| 2024-03-31 | $76 |
| 2023-12-31 | $125 |
| 2023-09-30 | $74 |
| 2023-06-30 | $49 |
| 2023-03-31 | $45 |
| 2022-12-31 | $40 |
| 2022-09-30 | $19 |
| 2022-06-30 | $-11 |
| 2022-03-31 | $53 |
| 2021-12-31 | $65 |
| 2021-09-30 | $48 |
| 2021-06-30 | $42 |
| 2021-03-31 | $29 |
| 2020-12-31 | $18 |
| 2020-09-30 | $35 |
| 2020-06-30 | $37 |
| 2020-03-31 | $16 |
| 2019-12-31 | $27 |
| 2019-09-30 | $25 |
| 2019-06-30 | $14 |
| 2019-03-31 | $12 |
| 2018-12-31 | $21 |
| 2018-09-30 | $11 |
| 2018-06-30 | $8 |
| 2018-03-31 | $4 |
| 2017-12-31 | $3 |
| 2017-09-30 | $6 |
| 2017-06-30 | $0 |
| 2017-03-31 | $-2 |
| 2016-12-31 | $-1 |
| 2016-09-30 | $6 |
| 2016-06-30 | $2 |
| 2016-03-31 | $-4 |
| 2015-12-31 | $-8 |
| 2015-09-30 | $-11 |
| 2015-06-30 | $-10 |
| 2015-03-31 | $-4 |
| 2014-12-31 | $4 |
| 2014-09-30 | $0 |
| 2014-06-30 | $-2 |
| 2014-03-31 | $1 |
| 2013-12-31 | $3 |
| 2013-09-30 | $-14 |
| 2013-06-30 | $-3 |
| 2013-03-31 | $-3 |
| 2012-12-31 | $-3 |
| 2012-09-30 | $-6 |
| 2012-06-30 | $-8 |
| 2012-03-31 | $-8 |
| 2011-12-31 | $-8 |
| 2011-09-30 | $-7 |
| 2011-06-30 | $-13 |
| 2011-03-31 | $-6 |
| 2010-12-31 | $-14 |
| 2010-09-30 | $-5 |
| 2010-06-30 | $-7 |
| 2010-03-31 | $-8 |
| 2009-12-31 | $-9 |
| 2009-09-30 | $-11 |
| 2009-06-30 | $-13 |
| 2009-03-31 | $-15 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $23.536B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $228.801B | 26.83 |
| Boston Scientific (BSX) | United States | $156.873B | 37.41 |
| Stryker (SYK) | United States | $150.304B | 30.59 |
| EssilorLuxottica (ESLOY) | France | $143.779B | 0.00 |
| Medtronic (MDT) | Ireland | $118.071B | 16.65 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.982B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.547B | 24.90 |
| ResMed (RMD) | United States | $41.283B | 29.52 |
| GE HealthCare Technologies (GEHC) | United States | $33.904B | 15.94 |
| Agilent Technologies (A) | United States | $33.716B | 21.78 |
| Terumo (TRUMY) | Japan | $26.887B | 31.86 |
| Koninklijke Philips (PHG) | Netherlands | $26.663B | 17.64 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.155B | 13.47 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.315B | 0.00 |
| Baxter (BAX) | United States | $12.599B | 9.73 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.925B | 29.11 |
| Lantheus Holdings (LNTH) | United States | $3.865B | 10.45 |
| Envista Holdings (NVST) | United States | $3.530B | 24.70 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.295B | 14.62 |
| Perrigo (PRGO) | Ireland | $3.287B | 8.21 |
| ICU Medical (ICUI) | United States | $3.126B | 21.28 |
| Haemonetics (HAE) | United States | $2.651B | 11.83 |
| LeMaitre Vascular (LMAT) | United States | $2.166B | 46.45 |
| Curaleaf Holdings (CURLF) | Canada | $2.148B | 0.00 |
| Acuren (TIC) | United States | $2.126B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.886B | 11.87 |
| Green Thumb Industries (GTBIF) | United States | $1.876B | 80.57 |
| AtriCure (ATRC) | United States | $1.854B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.508B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.305B | 15.41 |
| Neogen (NEOG) | United States | $1.247B | 19.79 |
| AdaptHealth (AHCO) | United States | $1.246B | 17.71 |
| BioLife Solutions (BLFS) | United States | $1.218B | 2543.00 |
| InMode (INMD) | Israel | $0.960B | 8.88 |
| Kestra Medical Technologies (KMTS) | United States | $0.924B | 0.00 |
| Valneva SE (VALN) | France | $0.745B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.699B | 0.00 |
| SNDL (SNDL) | Canada | $0.665B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.611B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.595B | 0.00 |
| ZimVie (ZIMV) | United States | $0.535B | 20.62 |
| Evolus (EOLS) | United States | $0.490B | 0.00 |
| Surmodics (SRDX) | United States | $0.488B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.475B | 16.36 |
| CeriBell (CBLL) | United States | $0.425B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.380B | 0.00 |
| Owens & Minor (OMI) | United States | $0.378B | 3.35 |
| Canopy Growth (CGC) | Canada | $0.362B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.340B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.302B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.301B | 0.00 |
| High Tide (HITI) | Canada | $0.292B | 0.00 |
| Omeros (OMER) | United States | $0.289B | 0.00 |
| Brainsway (BWAY) | Israel | $0.288B | 58.69 |
| Capricor Therapeutics (CAPR) | United States | $0.286B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.278B | 21.12 |
| TriSalus Life Sciences (TLSI) | United States | $0.254B | 0.00 |
| Cerus (CERS) | United States | $0.251B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.244B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.238B | 0.00 |
| Organigram Global (OGI) | Canada | $0.224B | 0.00 |
| Quanterix (QTRX) | United States | $0.214B | 0.00 |
| Exagen (XGN) | United States | $0.210B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.196B | 16.34 |
| FitLife Brands (FTLF) | United States | $0.176B | 21.66 |
| Biote (BTMD) | United States | $0.166B | 5.51 |
| Jushi Holdings (JUSHF) | United States | $0.147B | 0.00 |
| Jin Medical (ZJYL) | China | $0.128B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.115B | 0.00 |
| MacroGenics (MGNX) | United States | $0.109B | 0.00 |
| Fonar (FONR) | United States | $0.098B | 12.66 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Apyx Medical (APYX) | United States | $0.075B | 0.00 |
| Agape ATP (ATPC) | $0.069B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.060B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.058B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 32.10 |
| Zynex (ZYXI) | United States | $0.051B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.051B | 0.00 |
| Veru (VERU) | United States | $0.048B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 33.75 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 14.45 |
| Senestech (SNES) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Allurion Technologies (ALUR) | United States | $0.016B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| Sharps Technology (STSS) | United States | $0.015B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |